Proposed Mechanisms of Targeting COVID-19 by Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs
- 11 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Stem Cell Reviews and Reports
- Vol. 17 (1), 176-192
- https://doi.org/10.1007/s12015-020-10109-3
Abstract
With the outbreak of coronavirus disease (COVID-19) caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the world has been facing an unprecedented challenge. Considering the lack of appropriate therapy for COVID-19, it is crucial to develop effective treatments instead of supportive approaches. Mesenchymal stem cells (MSCs) as multipotent stromal cells have been shown to possess treating potency through inhibiting or modulating the pathological events in COVID-19. MSCs and their exosomes participate in immunomodulation by controlling cell-mediated immunity and cytokine release. Furthermore, they repair the renin-angiotensin-aldosterone system (RAAS) malfunction, increase alveolar fluid clearance, and reduce the chance of hypercoagulation. Besides the lung, which is the primary target of SARS-CoV-2, the heart, kidney, nervous system, and gastrointestinal tract are also affected by COVID-19. Thus, the efficacy of targeting these organs via different delivery routes of MSCs and their exosomes should be evaluated to ensure safe and effective MSCs administration in COVID-19. This review focuses on the proposed therapeutic mechanisms and delivery routes of MSCs and their exosomes to the damaged organs. It also discusses the possible application of primed and genetically modified MSCs as a promising drug delivery system in COVID-19. Moreover, the recent advances in the clinical trials of MSCs and MSCs-derived exosomes as one of the promising therapeutic approaches in COVID-19 have been reviewed. Graphical abstractKeywords
This publication has 170 references indexed in Scilit:
- Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trialBMC Medicine, 2013
- Mesenchymal stem cells: a double-edged sword in regulating immune responsesCell Death & Differentiation, 2012
- Negative Regulation of Lung Inflammation and Immunopathology by TNF-α during Acute Influenza InfectionThe American Journal of Pathology, 2011
- Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012Cell Death & Differentiation, 2011
- Concise Review: Mesenchymal Stem Cells for Acute Lung Injury: Role of Paracrine Soluble FactorsThe International Journal of Cell Cloning, 2011
- Bone marrow stromal cells use TGF-β to suppress allergic responses in a mouse model of ragweed-induced asthmaProceedings of the National Academy of Sciences of the United States of America, 2010
- Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lungProceedings of the National Academy of Sciences of the United States of America, 2009
- Liquid and surfactant delivery into pulmonary airwaysRespiratory Physiology & Neurobiology, 2008
- Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 productionNature Medicine, 2008
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006